Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Stemcentrx LlcfiledCriticalAbbvie Stemcentrx Llc
Publication of AR107223A1publicationCriticalpatent/AR107223A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Peptides Or Proteins
(AREA)
Abstract
Anticuerpos anti-UPK1B y conjugados de anticuerpo y fármaco, y métodos para el uso de los mencionados anticuerpos y conjugados de anticuerpo y fármaco anti-UPK1B para tratar el cáncer. Reivindicación 2: Un anticuerpo aislado que se une a UPK1B humana caracterizado porque comprende la SEQ ID Nº 1.Anti-UPK1B antibodies and antibody and drug conjugates, and methods for the use of said antibodies and anti-UPK1B antibody and drug conjugates to treat cancer. Claim 2: An isolated antibody that binds to human UPK1B characterized in that it comprises SEQ ID No. 1.
ARP160104000A2015-12-222016-12-22
DIRECTED ANTIBODIES AGAINST UPK1B AND METHODS FOR USE
AR107223A1
(en)
ANTIBODIES AGAINST THE ORPHANE RECEPTOR SIMILAR TO THE THIROSINE QUINASE 1 (ANTI-ROR1) RECEPTOR, BISPECIFIC ANTIBODIES THAT JOIN ROR1 AND THE CD3 ANTIGEN, AND METHODS FOR TREATMENT OF CANCER